Lesión renal aguda y anemia hemolítica autoinmune inducida por rifampicina, una complicación poco frecuente y potencialmente mortal

Andrés José  García-Montoya; Sebastián  Barrera-Escobar

doi:10.17533/10.17533/udea.iatreia.145

Autores/as

Andrés José García-Montoya IPS universitaria Clínica León XIII, Medellín, Colombia.
Sebastián Barrera-Escobar IPS Universitaria Clínica León XIII, Medellín, Colombia. https://orcid.org/0000-0001-5476-8013

DOI:

https://doi.org/10.17533/10.17533/udea.iatreia.145

Palabras clave:

Hemolisis, Lesión Renal Aguda, Rifampicina

Resumen

La rifampicina es un medicamento ampliamente utilizado para el tratamiento de diversas infecciones bacterianas con un amplio espectro de efectos adversos que varían desde reacciones leves hasta potencialmente fatales; la anemia hemolítica es un efecto adverso escasamente reportado en la literatura pero que puede tener un desenlace potencialmente fatal, reportamos así un caso de anemia hemolítica autoinmune asociada a lesión renal aguda en una paciente joven en segunda fase de tratamiento para tuberculosis pulmonar.

|Resumen

= 796 veces | HTML

= 0 veces| | PDF

= 265 veces|

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Andrés José García-Montoya, IPS universitaria Clínica León XIII, Medellín, Colombia.

Médico internista, IPS universitaria Clínica León XIII, Medellín, Colombia.

Sebastián Barrera-Escobar, IPS Universitaria Clínica León XIII, Medellín, Colombia.

Médico general de la IPS Universitaria Clínica León XIII, Medellín, Colombia.

Citas

(1) Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases. Am J Respir Crit Care Med. 2007 Feb 15;175(4):367–416. DOI 10.1164/rccm.200604-571ST.

(2) Chen CY, Chen HY, Chou CH, Huang CT, Lai CC, Hsueh PR. Pulmonary infection caused by nontuberculous mycobacteria in a medical center in Taiwan, 2005-2008. Diagn Microbiol Infect Dis. 2012 Jan;72(1):47-51. DOI 10.1016/j.diagmicrobio.2011.09.009.

(3) De Vriese AS, Robbrecht DL, Vanholder RC, Vogelaers DP, Lameire NH. Rifampicin-associated acute renal failure: pathophysiologic, immunologic, and clinical features. Am J Kidney Dis. 1998 Jan;31(1):108–15.

(4) Martinez E, Collazos J, Mayo J. Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Medicine (Baltimore). 1999 Nov;78(6):361–9.

(5) Girling DJ, Hitze KL. Adverse reactions to rifampicin. Bull World Health Organ. 1979;57(1):45–9.

(6) Muthukumar T, Jayakumar M, Fernando EM, Muthusethupathi MA. Acute renal failure due to rifampicin: a study of 25 patients. Am J Kidney Dis. 2002 Oct;40(4):690–6.

(7) Costiniuk CT, McCarthy AE, Talreja H, Zimmerman D, Liu TT, Owen E, Angel JB. Acute renal failure and disseminated intravascular coagulation associated with rifampin in tuberculosis treatment. Int J Tuberc Lung Dis. 2011 Mar;15(3):421.

(8) Manika K, Tasiopoulou K, Vlogiaris L, Lada M, Papaemmanouil S, Zarogoulidis K, Kioumis

I. Rifampicin-associated acute renal failure and hemolysis: a rather uncommon but severe

complication. Ren Fail. 2013 Sep;35(8):1179-81. DOI 10.3109/0886022X.2013.815567.

(9) Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003 Feb 15;167(4):603-62. DOI 10.1164/rccm.167.4.603.

(10) Covic A, Goldsmith DJ, Segall L, Stoicescu C, Lungu S, Volovat C, et al. Rifampicin-induced acute renal failure: a series of 60 patients. Nephrol Dial Transplant. 1998 Apr;13(4):924–9.

(11) Rosati S, Cherubini C, Iacomi F, Giannakakis K, Vincenzi L, Ippolito G, et al. Acute rifampicin-associated interstitial tubulopathy in a patient with pulmonary tuberculosis:

a case report. J Med Case Rep. 2013 Apr;7:106.

(12) Dhaliwal G, Cornett PA, Tierney LM. Hemolytic Anemia. Am Fam Physician. 2004;69(11):557-74.

(13) Croft JR, Swisher SN, Gilliland BC, Bakemeier RF, Leddy JP, Weed RI. Coombs’-Test Positivity Induced by Drugs: Mechanisms of Immunologic Reactions and Red Cell Destruction. Ann Intern Med. 1968 Jan 1;68(1):176–87. DOI 10.7326/0003-4819-68-1-176.

(14) Habibi B, Bretagne Y. Les antigènes de groupes sanguins peuvent être les cibles des conflits immunoallergiques médicamenteux à affinité érythrocytaire [Blood group antigens may be the receptors for immunoallergic drug complexes reacting with erythrocytes]. C R Seances Acad Sci III. 1983;296(15):693-6.

(15) Duran-Suarez JR, Martin-Vega C, Argelagues E, Massuet L, Ribera A, Triginer J. Red cell I antigen as immune complex receptor in drug-induced hemolytic anemias. Vox Sang. 1981;41(5–6):313–5.

(16) Pereira A, Sanz C, Cervantes F, Castillo R. Immune hemolytic anemia and renal failure associated with rifampicin-dependent antibodies with anti-I specificity. Ann Hematol. 1991 Jul;63(1):56–8.

(17) Lakshminarayan S, Sahn SA, Hudson LD. Massive haemolysis caused by rifampicin. Br Med J. 1973 May;2(5861):282–3.

(18) Sykes CA, Shepherd J, McGoldrick C, Kennedy N, Raafat A. A case of rifampicin-induced haemolysis. Int J Tuberc Lung Dis. 2019 Feb;23(2):239–40.

(19) Ahrens N, Genth R, Salama A. Belated diagnosis in three patients with rifampicin-induced immune haemolytic anaemia. Br J Haematol. 2002 May;117(2):441–3.